Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in diffuse cutaneous systemic sclerosis
NCT04680975Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Sanofi. Primary endpoint: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at 24 weeks. Started Mar 2021; status: terminated.
02
Drugs
belumosudil
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04680975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680975.